Antibody-Drug Conjugates The 21st Century Magic Bullets for Cancer /
The field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg®), the landscape has expanded drama...
Сохранить в:
| Соавтор: | |
|---|---|
| Другие авторы: | , |
| Формат: | Электронный ресурс eКнига |
| Язык: | английский |
| Опубликовано: |
Cham :
Springer Nature Switzerland : Imprint: Springer,
2025.
|
| Редактирование: | 2nd ed. 2025. |
| Серии: | AAPS Advances in the Pharmaceutical Sciences Series,
17 |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1007/978-3-031-83005-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Оглавление:
- 1 Antibody-Drug Conjugates: A Historical Review
- 2 Payloads of Antibody-Drug Conjugates
- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy
- 4 Linker Design for Antibody-Drug Conjugates
- 5 Formulation Development for Antibody-Drug Conjugates
- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates
- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates
- 8 Regulatory Considerations
- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy
- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal
- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate
- 12 Ado-Trastuzumab Emtansine
- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer
- 14 Summary and Future Directions.